Managing Growth Hormone Deficiency Across the Continuum of Care - Episode 9
Extension Data for Long-Acting GH Analog Lonapegsomatropin in Pediatric and Adult GHD
Weekly growth hormone cuts injections—learn how it’s designed, who benefits, and key safety unknowns for cancer survivors and diabetes.
This episode reviews the clinical trial data and extension studies for lonapegsomatropin, the first long-acting GH analog approved for pediatric GHD (2021), with additional discussion of adult outcomes from the Phase 3 foresiGHt trial.
Dr. Yang presents the pediatric extension data from the enliGHten trial. The approved starting dose for lonapegsomatropin in pediatric GHD is 0.24 mg/kg/week. Importantly, approximately 30% of trial patients required a dose reduction because average IGF-1 levels trended too high, leading to a lower mean dose of approximately 0.21 mg/kg/week in practice. Dr. Yang notes this mirrors real-world experience — some patients require downward titration to maintain IGF-1 in the target range.
The panel engages in a nuanced discussion about the clinical significance of elevated IGF-1 levels. While supraphysiologic IGF-1 is clearly harmful in conditions like acromegaly, the specific threshold at which mildly elevated IGF-1 from GH therapy becomes problematic is unknown. Current IGF-1 assays reflect circulating (primarily liver-derived) IGF-1, not local IGF-1 production at tissues such as growth plates — a limitation that constrains interpretation.
Dr. Garcia reviews adult data from the Phase 3 foresiGHt trial. In adults, lonapegsomatropin demonstrated comparable safety and efficacy to daily GH formulations, with statistically significant improvements in fat mass reduction and lean body mass gain versus placebo. Quality of life improvements were also noted. While fat mass changes appeared slightly more favorable with daily GH in the trial, no head-to-head statistical comparison was performed.
The episode reinforces that the key advantage of lonapegsomatropin — as with all long-acting analogs — is the potential for improved adherence through once-weekly dosing, which translates into better real-world outcomes.
In the next episode, “Extension Data for Other Long-Acting GH Analogs,” the panel reviews the REAL3 (pediatric) and REAL1 (adult) trial data for somapacitan, and discusses the pediatric approval and adult outcomes for somatrogon.
